Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that GlaxoSmithKline's Duodart (the fixed-dose combination of dutasteride and tamsulosin) will earn Decision Resources' proprietary clinical gold standard status in 2013 and through 2018 for the treatment of benign prostatic hyperplasia/male lower urinary tract symptoms due to its competitive advantage in overall efficacy over the current gold standard dutasteride (GlaxoSmithKline's Avodart, Taiho Pharmaceutical's Avolve).

The new report entitled Benign Prostatic Hyperplasia/Male Lower Urinary Tract Symptoms: More Convenient Therapies Targeting Improved Patient Compliance Are on the Horizon also finds that symptom improvement is the most important drug attribute influencing surveyed U.S. and European urologists' prescribing decisions in benign prostatic hyperplasia/male lower urinary tract symptoms. This finding also parallels anecdotal evidence provided by interviewed thought leaders, who indicate that alleviating symptoms is the paramount goal when treating benign prostatic hyperplasia/male lower urinary tract symptoms patients. For developers of novel therapies this means that the bar has been set high in terms of physician expectations for symptom improvement given that uroselective alpha blockers have largely fulfilled the need for a drug that relieves lower urinary tract symptoms (suggestive of benign prostatic hyperplasia) without generating serious side effects (such as orthostatic hypotension).

"To make significant inroads into the benign prostatic hyperplasia/male lower urinary tract symptoms market we believe novel agents would have to show symptom relief that is at least comparable to the relief provided by existing treatments and offer additional benefit such as relatively low rates of sexual side effects, infrequent dosing and earlier and significant improvement in disease modification," stated Decision Resources Therapeutic Area Director Melissa Stolper.

About the Report

Benign Prostatic Hyperplasia/Male Lower Urinary Tract Symptoms: More Convenient Therapies Targeting Improved Patient Compliance Are on the Horizon is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:       Gisselle Morales                             Elizabeth Marshall   Decision Resources                           Decision Resources, Inc.   781-296-2691                                 781-296-2563   gmorales@dresources.com                      emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Gisselle Morales, Decision Resources, +1-781-296-2691,
gmorales@dresources.com, or Elizabeth Marshall, Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Despite FDA's Letter to Merck Serono, Oral Cladribine is Still Expected to be the First Oral Disease-Modifying Therapy to Launch for Multiple Sclerosis in the United States

View Now